In the study on the use of CMS and CRIS classifications to predict adjuvant treatment response in stage II–III CRC in order to better predict CRIS-C patients (i.e., the subtype that significantly benefitted from adjuvant chemotherapy in stage II–III CRC) at higher risk of relapse after surgery, Allen et al. [94] evaluated T cell infiltration in specific tumor regions as well as CD8 and CD3 levels. The gene discussed is CD8A; the disease is neoplasm.